末梢神経障害治療の市場規模・シェア・展望・機会 (2022年～2030年)：適応症・治療 (薬理療法・非薬理療法)・エンドユーザー・地域別

主要参入事業者は製品の上市や承認などの成長戦略の採用に注力しており、これらが予測期間中の世界の末梢神経障害治療市場の成長を促進すると考えられています。

当レポートでは、世界の末梢神経障害治療の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制・償還環境、パイプラインの分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・規制・動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• パイプライン分析
• 償還シナリオ
• 疫学
• PEST分析
• 規制シナリオ
• 新製品の承認・発売
• 買収・提携
• 市場動向

第4章 世界の末梢神経障害治療市場：COVID-19の影響

• COVID-19がヘルスケア部門全体に与える影響
• COVID-19：疫学
• COVID-19の臨床試験と医薬品開発への影響

第5章 世界の末梢神経障害治療市場：適応症別

• 糖尿病性末梢神経障害
• 化学療法誘発性末梢神経障害
• 特発性末梢神経障害
• その他

第6章 世界の末梢神経障害治療市場：治療別

• 薬理療法

第7章 世界の末梢神経障害治療市場：エンドユーザー別

• 病院
• 外来センター
• その他

第8章 世界の末梢神経障害治療市場：地域別

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• ヒートマップ分析
  • Abbott Laboratories
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Johnson &Johnson
  • Reddy's Laboratories Ltd
  • Pfizer, Inc.
  • Cipla Inc.
  • Lupin Limited
  • Averitas Pharma, Inc.
  • NeuroBo Pharmaceuticals, Inc
• アナリストの見解

第10章 セクション

Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes. Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy.

Market Dynamics

Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain. Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period. For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.

Key features of the study:

• This report provides an in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy's Laboratories Ltd, Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., and NeuroBo Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Detailed Segmentation:

• Global Peripheral Neuropathy Treatment Market, By Indication :
• Diabetic Peripheral Neuropathy
• Chemotherapy-induced Peripheral Neuropathy
• Idiopathic Peripheral Neuropathy
• Others
• Global Peripheral Neuropathy Treatment Market, By Treatment :
• Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
• Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
• Global Peripheral Neuropathy Treatment Market, By End User :
• Hospital
• Ambulatory Centers
• Others
• Global Peripheral Neuropathy Treatment Market, By Region:

• North America
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange

o

• Others
• By End User
• Hospital
• Ambulatory Centers
• Others
• By Country
• U.S.
• Canada
• Latin America
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others

o

• By End User
• Hospital
• Ambulatory Centers
• Other
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • By Indication
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • Others
  • By Application
  • Pharmacological Therapies
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others
  • By End User
  • Hospital
  • Ambulatory Centers
  • Other
  • By Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Abbott Laboratories*
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company
• Johnson & Johnson
• Dr. Reddy's Laboratories Ltd
• Pfizer, Inc.
• Cipla Inc.
• Lupin Limited
• Averitas Pharma, Inc.
• NeuroBo Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Indication
  • Market Snapshot, By Treatment
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunity
• Impact Analysis
• Pipeline Analysis
• Reimbursement Scenario
• Epidemiology
• PEST Analysis
• Regulatory Scenario
• New Product Approvals/Launches
• Acquisition and Collaboration
• Market Trends

4. Global Peripheral Neuropathy Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

• COVID-19 Impact on Overall Healthcare Sector
• COVID-19 Epidemiology
• COVID-19 Impact on Clinical Trials and Drug Development

5. Global Peripheral Neuropathy Treatment Market, By Indication, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Diabetic Peripheral Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Chemotherapy-induced Peripheral Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Idiopathic Peripheral Neuropathy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Peripheral Neuropathy Treatment Market, By Treatment, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Pharmacological Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  • Pain Relievers
  • Anti-seizure Medications
  • Anti-depressants
  • Non-pharmacological Therapies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
  • Transcutaneous Electrical Nerve Stimulation
  • Plasma Exchange
  • Others

7. Global Peripheral Neuropathy Treatment Market, By End User, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Hospital
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Ambulatory Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)

8. Global Peripheral Neuropathy Treatment Market, By Region, 2017-2030, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2028
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• Heat Map Analysis
  • Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Reddy's Laboratories Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Cipla Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Averitas Pharma, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • NeuroBo Pharmaceuticals, Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us